274
In vitro inhibition of CYP2C9 by zafirlukast is consistent with clinical studies showing impaired clearance of  S-warfarin and enhanced anti-thrombotic effects, although the in vitro IC(50) value is higher than the usual range of clinically relevant plasma concentrations.
 impaired clearance of  S-warfarin and enhanced anti-thrombotic effects: Effect; zafirlukast: Treatment; zafirlukast: Treatment.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: potential therapeutic event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Treatment.Time_elapsed, Subject.Disorder, Subject.Race, Treatment.Route, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 impaired clearance of  S-warfarin and enhanced anti-thrombotic effects: Effect; zafirlukast: Treatment; zafirlukast: Treatment.Drug